Introduction
============

Pulmonary marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) that arises from the bronchial-associated lymphoid tissue is known as bronchial-associated lymphoid tissue lymphoma.[@b1-ott-11-555],[@b2-ott-11-555] Pulmonary MALT lymphoma is a rare disease constituting \<1% of all malignant lymphomas, but it is the most common histologic subtype of lung lymphoma.[@b3-ott-11-555]

Pulmonary MALT tends to occur in old-aged patients. The majority of patients are asymptomatic; in symptomatic patients, nonspecific pulmonary symptoms (such as cough, sputum, chest pain, dyspnea) are the most common.[@b4-ott-11-555] Pulmonary lesions are commonly discovered via a routine chest radiographic study incidentally, and the majority of patients present with localized disease. The commonest presentation is that of a solitary, well-defined nodule found on routine X-ray examination. Single or multiple nodules or areas of consolidation constitute the most frequently observed patterns on computerized tomography (CT) scans.[@b5-ott-11-555],[@b6-ott-11-555] Less commonly, there may be multiple nodules and/or a pleural effusion.[@b7-ott-11-555] Treatment options range from simple surgical excision to surgery followed by radiotherapy or chemotherapy alone.[@b4-ott-11-555],[@b7-ott-11-555] Due to the lack of randomized controlled trials and favorable response to different therapeutic modalities incorporated during the course of the disease, there are no standard treatment protocols or guidelines for pulmonary MALT lymphoma. Although quite a few reports have been published regarding pulmonary MALT lymphoma, the optimal treatment for this condition is not thoroughly elucidated. In this retrospective analysis, we summarize the clinical features and our therapeutic experience of 18 primary pulmonary MALT lymphoma patients in order to collect information about the optimal treatment modality.

Patients and methods
====================

Patients
--------

We retrospectively evaluated clinical data of 18 patients who were diagnosed with pulmonary MALT lymphoma from April 1995 to April 2016 at the Chinese People's Liberation Army General Hospital. Inclusion in this study required an initial diagnosis of pulmonary MALT lymphoma according to the World Health Organization criteria and primary site in the lungs.[@b8-ott-11-555]

The following clinical data were obtained from the records: patients' gender, age, performance status (PS), clinical stage, International Prognostic Index (IPI), respiratory symptoms, the presence of B symptoms, past history, blood count, erythrocyte sedimentation rate (ESR), lactic dehydrogenase level, β2-microglobulin (β2-MG) level, radiologic findings, bone marrow findings, date of diagnosis, diagnosis procedures, histology, type of treatment, treatment response, date of progression, date of last follow-up and cause of death. Response criteria were defined according to the World Health Organization criteria for response.[@b9-ott-11-555] The IPI score was recorded according to the published criteria.[@b10-ott-11-555] The staging was based upon the Ann Arbor staging system.[@b11-ott-11-555]

The study was conducted in accordance with the Declaration of Helsinki. All the patients signed written informed consent, and this study was approved by the Ethical Committee of the People's Liberation Army General Hospital.

Statistical methodology
-----------------------

SPSS version 17.0 (SPSS, Chicago, IL, USA) was used for data processing and analysis. Overall survival (OS) and progression-free survival (PFS) curves were estimated by the Kaplan--Meier method. OS was measured from the date of diagnosis to the date of death or the last follow-up visit. PFS was calculated from the end of induction therapy to the date of disease progression/relapse or death in patients who received any treatment. Duration of follow-up was measured from the date of diagnosis to the last follow-up or date of death. All patients with no progression or who were alive at the last follow-up date were considered right censored. Survival rates were compared for statistical differences by log-rank analyses. All statistical tests were two-sided, and *P*\<0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

From our database, we could identify a total of 18 consecutive patients with pulmonary MALT lymphoma diagnosed and treated at our institution from April 1995 to April 2016. The clinical characteristics of the 18 patients are presented in [Table 1](#t1-ott-11-555){ref-type="table"}. The male:female ratio of the 18 patients was 11:7. The median age at diagnosis was 55 (range 34--67) years. Seven patients (38.9%) were older than 60 years. Ten patients (55.6%) presented good PS (0--1), while 14 patients (77.8%) presented at diagnosis with late stage disease (stages III--IV). IPI was low risk in 1 patient, low-intermediate risk in 11 patients, high--intermediate risk in 2 patients and high risk in 4 patients. B symptoms were observed in 3 patients. Six patients (33.3%) had a history of smoking and 5 patients (27.8%) had tuberculosis. With the exception of 4 patients (22.2%) who exhibited no symptoms, patients initially presented with cough (38.9%), expectoration (33.3%), dyspnea (27.8%) and chest pain (33.3%). Hemoglobin level and serum lactate dehydrogenase (LDH) activity were normal in most patients (94.4%). Ten patients (10/14, 71.4%) had elevated β2-MG, and 6 patients (6/15, 40%) showed elevated ESR. Four patients (22.2%) were infected with *Helicobacter pylori*. None of the evaluated patients were infected by human immunodeficiency virus, while 5 patients (27.8%) were infected with hepatitis B virus.

Diagnostic procedures
---------------------

In symptomatic patients with pulmonary MALT lymphoma, the median duration of symptoms before definitive diagnosis was 3 (range 1--60) months. All patients underwent thoracic CT scan or chest X-ray. A common radiologic pattern, such as single or multiple pulmonary nodules, masses or mass-like areas of consolidation, localized in the center or in the periphery of parenchyma was not definable.

Diagnostic procedures of patients with pulmonary MALT lymphoma are presented in [Table 2](#t2-ott-11-555){ref-type="table"}. Surgical lung biopsy was performed in 6 patients (video-assisted thoracoscopy, n=2; open lung biopsy, n=4), transbronchial lung biopsy in 7 patients and CT-guided transthoracic lung biopsy in 5 patients.

Histology
---------

The pulmonary structure was effaced by abnormal lymphocyte infiltration, predominantly localized along bronchovascular bundles, interlobular septa and visceral pleura. Morphologically, the lymphoma cells exhibited a spectrum of cytologic features (small round cells, centrocyte-like cells, monocytoid cells). The presence of lymphoepithelial lesion was frequent and involved bronchiolar and bronchial epithelial structures. Immunohistochemical staining was performed in all 18 cases, with all neoplastic lymphocytes staining positive for CD20 and CD79a expression. There was also scattered positive staining for BCL2 in 10 cases. CD10, CD5 and CyclinD1 expression were negative for most neoplastic lymphocytes. Examples of representative pathologic images of tissue from patients in this study are shown in [Figure 1](#f1-ott-11-555){ref-type="fig"}.

Treatment and response
----------------------

Treatment and response are reported in [Table 3](#t3-ott-11-555){ref-type="table"}. Of the 18 patients, 1 patient did not receive any treatment, while 17 patients received various combinations of treatment. One patient underwent surgery alone, 6 patients were treated with surgery plus chemotherapy and 10 patients received chemotherapy alone. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) and CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) were administered to 9 and 2 patients, respectively. R-COP (rituximab, cyclophosphamide, vincristine and prednisolone) was administered to 1 patient. Two patients were treated with R-FND (rituximab, fludarabine, mitoxantrone and dexamethasone). R-FC (rituximab, fludarabine and cyclophosphamide) was administered to 1 patient. Rituximab was used in combination with chemotherapy in 14 patients, including surgery followed by rituximab-containing chemotherapy in 4 patients and rituximab-containing chemotherapy alone in 10 patients. No patient was treated with radiotherapy. The responses to treatment were a complete response (CR) in 8 patients, including 1 who received surgery alone, partial response (PR) in 6 patients and stable disease in 3 patients.

Outcome
-------

The median time between diagnosis and start of treatment was 12 (range 0--68) days. Five patients experienced progression/relapse after first-line treatment (median time to progression was 72 months, range 1--204). With a median follow-up of 93 (range 12--204) months, 2 patients died from unknown causes. [Figure 2](#f2-ott-11-555){ref-type="fig"} shows the Kaplan--Meier curves of OS and PFS of the entire population. The median PFS was 6 years and the estimated 5- and 10-year OS rates were 94.1% and 83.7%, respectively. [Figure 3](#f3-ott-11-555){ref-type="fig"} shows the differences in PFS according to treatment modality; we found no difference between the chemotherapy group and the surgery in combination with chemotherapy group (*P*=0.24).

Discussion
==========

Our data confirm the previously described indolent behavior of pulmonary MALT lymphoma.[@b12-ott-11-555]--[@b15-ott-11-555] The median age of the 18 patients in our study was 55 years, similar to those of the other series.[@b12-ott-11-555],[@b16-ott-11-555] Although previous studies reported female predominance[@b16-ott-11-555]--[@b18-ott-11-555] or an equal number of male and female patients,[@b19-ott-11-555],[@b20-ott-11-555] we found male predominance, which was consistent with some previous studies.[@b12-ott-11-555],[@b15-ott-11-555],[@b21-ott-11-555] In this study, about 77.8% of patients were symptomatic and they usually reported nonspecific pulmonary symptoms such as cough, expectoration, dyspnea and chest pain, while a minority of patients (16.7%) experienced constitutional symptoms such as fever, night sweats and weight loss. These characteristics are summarized in [Table 4](#t4-ott-11-555){ref-type="table"}. As mentioned in the preceding text, 77.8% of the patients were in stage III/IV, and therefore, we cannot exclude that lung was not the primary site of the disease. Most patients presented good PS; although 71.4% patients had elevated β2-MG levels, most patients had no adverse biologic prognostic factors such as anemia, elevated LDH or elevated ESR. Our series confirmed the characteristic indolent clinical presentation of pulmonary MALT lymphoma.

Many investigators believed that pulmonary MALT lymphoma is not a normal constituent of human lungs and rather its development is driven by long-term exposure to various antigenic stimuli.[@b22-ott-11-555]--[@b24-ott-11-555] Smoking, chronic inflammatory disease and various autoimmune diseases, such as Sjoren's syndrome and rheumatoid arthritis, have been believed to be the etiological agents for pulmonary MALT lymphoma, but the pathogenesis of this disease remains unclear.[@b7-ott-11-555],[@b9-ott-11-555],[@b25-ott-11-555]--[@b27-ott-11-555] In this study, 33.3% of patients had a smoking history, which was lower than that of other studies.[@b15-ott-11-555],[@b20-ott-11-555],[@b28-ott-11-555] So, we cannot definitively exclude its possible role in pathogenesis of the disease. Further studies are needed to address this issue. Another notable finding in our study was that 27.8% of the patients had a history of tuberculosis.

In our series, the radiographic appearance of pulmonary MALT lymphoma was represented as pulmonary nodules and as lung masses or mass-like areas of consolidation. Pleural effusion and mediastinal or hilar lymphadenopathy were rare in our series, consistent with previous observations.[@b5-ott-11-555],[@b7-ott-11-555],[@b29-ott-11-555] This suggested that the radiographic presentation of pulmonary MALT lymphomas is not specific, but variable in different patients. Pulmonary MALT lymphoma could be diagnosed only by pathologic methods. CT-guided transthoracic lung biopsy and open thoracotomy or video-assisted thoracoscopy lung biopsy are the common methods to obtain samples. A previous study had reported the positive predictive rate of puncture biopsy under CT guidance for diagnosing pulmonary non-Hodgkin's lymphoma was only 25%.[@b16-ott-11-555] However, in our study, using ancillary immunohistochemical staining, 12 (66.7%) patients were diagnosed by minimally invasive procedures, including CT-guided transthoracic lung biopsy and transbronchial lung biopsy without surgery. This finding may be attributed to the wide use of examination of immunohistochemical staining and less-invasive diagnostic procedures before performing surgery.

In agreement with the previous observations, our data showed the impressively favorable clinical course of pulmonary MALT lymphoma regardless of the treatment. The optimal management of lung extranodal marginal zone lymphomas with regard to surgery, chemotherapy and radiation therapy alone or in combination, as well as abstention from therapy, has to be clearly determined. Some experts have suggested that surgery should not be the first choice of treatment, the aim of which should be to preserve lung function.[@b30-ott-11-555]--[@b32-ott-11-555] Oh et al[@b15-ott-11-555] found no differences in OS between patients given chemotherapy and those who underwent surgery. But Lee et al found complete surgical resection may lead to favorable treatment outcomes for low-stage pulmonary MALT lymphoma.[@b33-ott-11-555] However, in our study, 14 patients presented at diagnosis with late stage disease (stages III--IV) and only 1 patient accepted surgery alone. Most of our patients were managed by chemotherapy. Rituximab was used in combination with chemotherapy in 14 patients. We observed 6 cases of CR, 5 PR cases and 3 cases of stable disease. Ahmed et al[@b20-ott-11-555] reported the results of 10 patients treated with rituximab alone or in combination with chemotherapy, with 2 achieving CR and 8 achieving PR. It is, therefore, possible that rituximab has a potential curative power in patients with pulmonary MALT lymphoma. During the follow-up period, 2 cases died, disease progression was noted in 5 patients overall (27.8%) and 1 of them developed disease progression during the initial observation period. The estimated 5- and 10-year OS rates were 94.1% and 83.7%, respectively. Our results were in agreement with most of the previous observations that showed a slow rate of progression and a favorable course in pulmonary MALT lymphoma.[@b13-ott-11-555],[@b15-ott-11-555],[@b20-ott-11-555],[@b34-ott-11-555] In our series, we noted no difference in PFS between chemotherapy and surgery combined with chemotherapy. So, operation might not be the first choice to preserve the lung function and avoid the risks of surgery.

Limitations of this study should be acknowledged. First, this was a retrospective study with a relatively small number of patients. Second, patients with pulmonary MALT lymphoma were included in this study based on a single tertiary care medical center. Therefore, it should be further confirmed through multicenter, large-scale clinical data.

Conclusion
==========

Our study revealed that pulmonary MALT lymphoma tended to be an indolent disease. We found a male preponderance. The elevation of LDH was rare in our patients. Lung nodules and masses or mass-like areas of consolidation were the common radiographic findings. With CT-guided transthoracic lung biopsy and transbronchial lung biopsy, invasive procedures might be a suitable option for diagnosis of pulmonary MALT lymphoma. In order to preserve the lung function and reduce the risks associated with surgery, chemotherapy might be an optimal choice for the treatment of pulmonary MALT lymphoma.
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![Morphology and immunophenotyping images of tissue from the patients with pulmonary MALT lymphoma.\
**Notes:** (**A**) The pulmonary structure was effaced by abnormal lymphocyte infiltration, predominantly localized along bronchovascular bundles (HE staining, original magnification ×200). (**B**--**D**) The neoplastic lymphocytes exhibited strong and uniform membrane staining for (**B**) CD20 and (**C**) CD79a expression is positive, but (**C**) CyclinD1, (**D**) CD10 and CD5 expression were negative for neoplastic lymphocytes (immunohistochemistry staining, original magnification ×200).\
**Abbreviation:** MALT, mucosa-associated lymphoid tissue.](ott-11-555Fig1){#f1-ott-11-555}

![OS and PFS of 18 pulmonary MALT lymphoma patients.\
**Notes:** (**A**) The OS curve of 18 patients with pulmonary MALT lymphoma. The estimated 5- and 10-year OS rates were 94.1% and 83.7%, respectively. (**B**) Kaplan--Meier estimate of the PFS of 18 patients with pulmonary MALT lymphoma. The median PFS was 6 years.\
**Abbreviations:** OS, overall survival; PFS, progression-free survival; MALT, mucosa-associated lymphoid tissue.](ott-11-555Fig2){#f2-ott-11-555}

![Progression-free survival curve according to surgery and chemotherapy in pulmonary MALT lymphoma patients.\
**Abbreviation:** MALT, mucosa-associated lymphoid tissue.](ott-11-555Fig3){#f3-ott-11-555}

###### 

Characteristics of all pulmonary MALT lymphoma patients

  Characteristics        Number of patients   Percent
  ---------------------- -------------------- -----------
  Gender                                      
   Male/female           11/7                 61.1/38.9
  Age, years                                  
   Median (range)        55 (34--67)          
   ≥60/\<60              7/11                 38.9/61.1
  PS (ECOG)                                   
   0--1/2                10/8                 55.6/44.4
  Stage                                       
   I                     2/18                 11.1
   II                    2/18                 11.1
   III                   1/18                 5.6
   IV                    13/18                72.2
  IPI                                         
   L                     1/18                 5.6
   LI                    11/18                61.1
   HI                    2/18                 11.1
   H                     4/18                 22.2
  B symptoms                                  
   Absent/present        15/3                 83.3/16.7
  Past history                                
   Smoking               6/18                 33.3
   Tuberculosis          5/18                 27.8
  Respiratory symptoms                        
   Cough                 7/18                 38.9
   Expectoration         6/18                 33.3
   Dyspnea               5/18                 27.8
   Chest pain            6/18                 33.3
   No symptoms           4/18                 22.2
  Hemoglobin \<12 g/dL   1/18                 5.6
  Elevated LDH           1/18                 5.6
  Elevated β2-MG         10/14                71.4
  Elevated ESR           6/15                 40.0
  HP positive            4/18                 22.2
  Hepatitis B virus      5/18                 27.8

**Notes:** Data presented as mean (range) or n (%). B symptoms include weight loss, fever and night sweats.

**Abbreviations:** MALT, mucosa-associated lymphoid tissue; PS, performance status; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; L, low risk; LI, low--intermediate risk; HI, high--intermediate risk; H, high risk; LDH, lactate dehydrogenase; β2-MG, β2-microglobulin; ESR, erythrocyte sedimentation rate; HP, *Helicobacter pylori*.

###### 

Diagnostic procedures of patients with pulmonary MALT lymphoma

  Procedures                            Number of patients                                Percent
  ------------------------------------- ------------------------------------------------- ---------
  Surgical biopsy                                                                         
   Video-assisted thoracoscopy          2/18                                              11.1
   Open lung biopsy                     4/18                                              22.2
  Transbronchial lung biopsy            7/18                                              38.9
  CT-guided transthoracic lung biopsy   5[\*](#tfn3-ott-11-555){ref-type="table-fn"}/18   27.8

**Note:**

One of five patients could not be diagnosed by transbronchial lung biopsy.

**Abbreviations:** MALT, mucosa-associated lymphoid tissue; CT, computed tomography.

###### 

Treatment of pulmonary MALT lymphoma

  Modality      Number of patients   CR (%)   PR (%)   SD (%)   NE (%)
  ------------- -------------------- -------- -------- -------- --------
  Surgery       7                                               
   Alone        1                    1                          
    +Chemo      2                    1 (50)   1 (50)            
    +R-chemo    4                    2 (50)   2 (50)            
  R+chemo       10                   4 (40)   3 (30)   3 (30)   
  Observation   1                                               1

**Note:** Data presented as n (%).

**Abbreviations:** MALT, mucosa-associated lymphoid tissue; CR, complete response; PR, partial response; SD, stable disease; NE, not evaluable; R, rituximab; chemo, chemotherapy.

###### 

Clinical presentation compared with other reports

                       Present study   Ogusa et al[@b21-ott-11-555]   Oh et al[@b15-ott-11-555]   Ahmed et al[@b20-ott-11-555]   Arkenau et al[@b12-ott-11-555]   Borie et al[@b13-ott-11-555]
  -------------------- --------------- ------------------------------ --------------------------- ------------------------------ -------------------------------- ------------------------------
  Population           China           Japan                          Korea                       Canada                         UK                               France
  Number of patients   18              16                             61                          22                             10                               63
  Median age (years)   55              58                             60                          61                             56                               60
  Male (%)             61              69                             57                          50                             70                               53
  B symptoms (%)       17              6                              16                          14                             0                                22
  Asymptomatic (%)     22.2            88                             41                          41                             20                               36
